Journals / Bezmiâlem Science / 2020 / Cilt: 8 - Sayı: 3

Potential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatment

SARS-CoV-2’ye Yönelik Potansiyel Tedavi Yaklaşımları ve İlaç Taşıyıcı Sistemlerin Tedavide Değerlendirilmesi

Pages
62–70
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, therapeutic approaches that may reduce and treat the severity of the disease by preventing ACE-2 mediated entry of viruses are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The severe acute respiratory syndrome-coronaviruse-2 (SARSCoV-2) genome is packaged in a helical nucleocapsid surrounded by a lipid bilayer.
📊
Key Findings & Data:Angiotensin converting enzyme-2 (ACE-2) has been identified as a functional receptor for coronaviruses, including SARS-CoV and SARS-CoV-2.
💡
Conclusion & Impact:In this review, therapeutic approaches that may reduce and treat the severity of the disease by preventing ACE-2 mediated entry of viruses are discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The severe acute respiratory syndrome-coronaviruse-2 (SARSCoV-2) genome is packaged in a helical nucleocapsid surrounded by a lipid bilayer. The virus envelope contains at least three viral proteins called spike protein (S), membrane protein (M) and envelope protein (E). While M and E form the structure of the virus, S protein is the leading agent of the entry of viruses into the host. Angiotensin converting enzyme-2 (ACE-2) has been identified as a functional receptor for coronaviruses, including SARS-CoV and SARS-CoV-2. Viral fusion is the main step in the onset of SARS-CoV-2 infection. It is thought that drugs that prevent spike protein and ACE-2 fusion, drugs acting on the renin-angiotensinaldesterone system, and a high dose ACE-2 can act on this fusion mechanism and take part in COVID-19 treatment. In this context, especially nano-sized liposomal carriers attract attention due to their biocompatibility and cell-like structures in the treatment of infectious diseases. There are studies in which liposomes are also used as a secondary therapeutic to support traditional anti-infective drugs. In this review, therapeutic approaches that may reduce and treat the severity of the disease by preventing ACE-2 mediated entry of viruses are discussed.

Özet

Şiddetli akut solunum yolu enfeksiyonu sendromu-koronavirüs-2 (SARS-CoV-2) genomu, lipit çift tabakası ile çevrelenen sarmal bir nükleokapsid içine paketlenmiştir. Virüs zarfı, spike proteini (S), zar proteini (M) ve zarf proteini (E) olarak isimlendirilen en az üç viral protein içermektedir. M ve E virüsün yapısını oluştururken, S proteini virüslerin konakçıya girişinin önde gelen aracısıdır. Anjiyotensin dönüştürücü enzim-2 (ACE-2), SARS-CoV ve SARS-CoV-2 dahil koronavirüsler için fonksiyonel bir reseptör olarak tanımlanmıştır. Viral füzyon SARS-CoV-2 enfeksiyonunun başlangıcında temel adımı oluşturmaktadır. Spike protein ve ACE2 füzyonunu engelleyen ilaçların, renin-anjiyotensin-aldesteron sistemi üzerine etki eden ilaçların ve ekses dozda ACE-2’nin bu füzyon mekanizması üzerine etki ederek COVİD-19 tedaviside yer alabileceği düşünülmüştür. Bu bağlamda özellikle nanoboyutlu lipozomal taşıyıcılar, enfeksiyöz hastalıkların tedavisinde biyo-uyumlulukları ve hücreye benzer yapıları nedeniyle dikkat çekmektedir. Lipozomların geleneksel anti-enfektif ilaçları desteklemek için ikincil bir terapötik olarak da kullanıldığı çalışmalar bulunmaktadır. Bu derlemede virüslerin ACE-2 aracılı girişini engelleyerek hastalığın şiddetini azaltma ve tedavi etme ihtimali olan terapötik yaklaşımlar ele alınmıştır

🔖

Cite This Article

ÇOMOĞLU, T., ARISOY, S. (2022). Potential Treatment Approaches to SARS-CoV-2 and Evaluation of Drug Carrier Systems in Treatment. Bezmiâlem Science, Cilt: 8 - Sayı: 3, 62–70. https://ajindex.com/articles/464077

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Akbabaa M, Kurtb B, Nazlıcanc E. A New Coronavirus Outbreak: MERS-CoV. Turk J Public Health 2014;12:217-27
  2. KLİMUD. Yeni Koronavirüs (‘’Novel Coronavirus’’ 2019-nCoV) - KLİMUD Klinik Viroloji Çalışma Grubu Bilgi Notu 2020. Available from:
  3. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60
  4. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Statpearls: StatPearls Publishing; 2020
  5. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315-31
  6. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012;4:1011-33
  7. Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother 2020;16:1232-8
  8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586-90
  9. FIP. COVID-19: Klinik Bilgi ve Tedavi Kılavuzları. 2020. Available from:
  10. Belete TM. A review on Promising vaccine development progress for COVID-19 disease. Vacunas. Amsterdam: Elseiver; 2020
  11. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020;382:1653-9
  12. Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J Transl Med 2020;18:1-3
  13. Shih H-I, Wu C-J, Tu Y-F, Chi C-Y. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J 2020;43:351- 4
  14. Ni L, Zhu J, Zhang J, Yan M, Gao GF, Tien P. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptadrepeat regions of the spike protein S2 domain. Biochem Biophys Res Commun 2005;330:39-45
  15. Sempowski GD, Saunders KO, Acharya P, Wiehe KJ, Haynes BF. Pandemic preparedness: d